CoChat

Inflammatory and Neurodegenerative Pathways in Depression: A New Avenue for Antidepressant Development?

Catena-Dell'Osso, M., Bellantuono, C., Consoli, G., Baroni, S., Rotella, F., Marazziti, D. · 2011 · Current Medicinal Chemistry
Cited by 148

The DOI matches its Crossref record.

Abstract

The latest advancement in neurobiological research provided an increasing evidence that inflammatory and neurodegenerative pathways play a relevant role in depression. Preclinical and clinical studies on depression highlighted an increased production of inflammatory markers, such as interleukin (IL)-1, IL-6, tumor necrosis factor-α and interferon- αand γ. On the other hand, acute and chronic administration of cytokines or cytokine inducers were found to trigger depressive symptoms. According to the cytokine hypothesis, depression would be due to a stress-related increased production of pro-inflammatory cytokines that, in turn, would lead to increased oxidative and nitrosative brain damage and to indoleamine 2,3 dioxygenase (IDO) induction, with production of tryptophan (TRP) catabolites along the IDO pathway (TRYCATs) and consequent reduced availability of TRP and serotonin (5-HT). Cytokines would also play a role in the onset of the glucocorticoid resistance, underlying the overdrive of the hypothalamic-pituitary-adrenal axis. Therefore, the activation of the inflammatory and neurodegenerative pathways would lead to the brain damage observed in depression through both reduced neurogenesis and increased neurodegeneration. Besides the 5-HT system, other targets, possibly within the I&ND pathways, should be considered for the future treatment of depression: cytokines and their receptors, intracellular inflammatory mediators, IDO, TRYCATs, glucocorticoid receptors, neurotrophic factors may all represent possible therapeutic targets for novel antidepressants. In addition, it should be also clarified the role of the existing antiinflammatory drugs in the treatment of depression, and those compounds with the anti-inflammatory and anti-oxidative properties should be examined either as monotherapy or adjunctive therapy. In conclusion, the molecular inflammatory and neurodegenerative pathways might provide new targets for antidepressant development and might be crucial to establish a rational treatment of depression aimed, hopefully, to its causal factors. Keywords: Cytokines, depression, inflammation, neurodegeneration, neurogenesis, glucocorticoid-resistance, indolamine, 2,3 dioxygenase, interleukin (IL)-1, tryptophan, glucocorticoid resistance, anti-inflammatory, anti-oxidative, psychomotor, serotonin, cerebrospinal fluid, microglia, astrocytes, intraperitoneal lipopolysaccharide, hypothalamus, acetylsalicylic acid, poly-unsatured fatty acids, kynurenine, glutamate, dexamethasone, glucocor-ticoid receptors, MMTV-luciferase activity, neuroinflammation, striatum, nitro-bovine serum albumin, S-nitrosylation, enkephalines, glucocorticoids, serendipity

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/092986711794088353

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 148

Metadata

Authors
Catena-Dell'Osso, M., Bellantuono, C., Consoli, G., Baroni, S., Rotella, F., & Marazziti, D.
Venue
Current Medicinal Chemistry
Published
2011-01-01
Volume
18
Issue
2
Pages
245-255
ISSN
0929-8673 (ISSN-L)
OpenAlex
W2125093934
Cited by
148
References
0
FWCI
4.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inflammatory and Neurodegenerative Pathways in Depression: A New Avenue for Antidepressant Development? https://app.cochat.ai/papers/10.2174/092986711794088353
The paper
Catena-Dell'Osso, M., Bellantuono, C., Consoli, G., Baroni, S., Rotella, F., & Marazziti, D. (2011). Inflammatory and Neurodegenerative Pathways in Depression: A New Avenue for Antidepressant Development? Current Medicinal Chemistry. https://doi.org/10.2174/092986711794088353

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.